When domperidone (Motilium) is used under medical supervision, the following dosing information applies: Adults and adolescents ≥12 years of age and weighing ≥35 kg, and children <12 years of age and weighing ≥35 kg: The dose of domperidone (Motilium) should be the lowest effective dose for the individual situation (typically 30 mg/day) and can be increased if necessary to a maximum daily oral dose of 40 mg.
Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. If nausea and vomiting persists for longer than one week, patients should consult their physician. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed. (See Table 2.)
Adults and adolescents (≥12 years of age) weighing <35 kg: The dose of domperidone (Motilium) should be the lowest effective dose. The total daily dose is dependent on body weight.
Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed. Film‑coated tablets and orodispersible tablets are unsuitable for use in adults and adolescents weighing less than 35 kg.
Infants and children <12 years of age and weighing <35 kg: The efficacy of Motilium has not been established in infants and children <12 years of age and weighing <35 kg.
When Domperidone (Motilium) is used over‑the‑counter, the following dosing information applies: Adults and adolescents 12-60 years of age and weighing ≥35 kg: Domperidone (Motilium) can be taken as 10 mg administered up to 3 times a day to a maximum daily dose of 30 mg.
Continuous use of domperidone (Motilium) without medical consultation should not exceed 7 days for the treatment of acute nausea and vomiting and 14 days for dyspeptic symptom complex.
Adults >60 years of age: Patients older than 60 years of age should consult their physician before taking Domperidone (Motilium).
Infants and children <12 years old: Domperidone (Motilium) should not be administered to children <12 years old and weighing ≥35 kg unless prescribed for use.
The efficacy of Motilium has not been established in infants and children <12 years of age and weighing <35 kg.
Prescription and Non-prescription Use: Renal impairment: Since the elimination half‑life of domperidone is prolonged in severe renal impairment (serum creatinine >6 mg/100 mL, i.e. >0.6 mmol/L), the dosing frequency of domperidone (Motilium) should be reduced to once or twice daily, depending on the severity of the impairment, and the dose may need to be reduced. Patients with severe renal impairment should be reviewed regularly (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: Domperidone (Motilium) is contraindicated for patients with moderate (Child‑Pugh 7 to 9) or severe (Child‑Pugh >9) hepatic impairment (see Contraindications). Dose adjustment is not required for patients with mild (Child‑Pugh 5 to 6) hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Sign Out